A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Escalating Single Dose of Albinterferon Alfa 2b (Alb-IFN), Recombinant Human Albumin-Interferon Alfa Fusion Protein in Japanese Chronic Hepatitis C Patients
Phase of Trial: Phase I
Latest Information Update: 20 May 2016
At a glance
- Drugs Albinterferon alfa 2B (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Novartis
- 10 Aug 2010 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 10 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Feb 2010 Planned end date changed from 1 Sep 2009 to 1 Sep 2010 as reported by ClinicalTrials.gov.